Role of Supportive Care for Terminal Stage Hepatocellular Carcinoma

Journal of Clinical and Experimental Hepatology

Volumn 4, Issue , 2014, Pages S130-S139

  Kumar, Manoj ^a   Panda, Dipanjan ^a  

^a INSTITUTE OF LIVER AND BILIARY SCIENCES   (India)

Author keywords

Hepatitis B virus (HBV); hepatitis C (HCV); hepatocellular carcinoma (HCC)

Indexed keywords

CODEINE; CORTICOSTEROID; CYCLOOXYGENASE 2 INHIBITOR; FENTANYL; HYDROMORPHONE; METHADONE; MORPHINE; NARCOTIC ANALGESIC AGENT; NONSTEROID ANTIINFLAMMATORY AGENT; OXYCODONE; PARACETAMOL; PETHIDINE;

ANOREXIA; ASCITES; CACHEXIA; CANCER PAIN; CANCER PALLIATIVE THERAPY; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CONSTIPATION; COPING BEHAVIOR; DRUG USE; FATIGUE; HUMAN; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; MALAISE; MALNUTRITION; NAUSEA; NAUSEA AND VOMITING; NUTRITIONAL SUPPORT; PRIORITY JOURNAL; PRURITUS; PSYCHOSOCIAL CARE; REVIEW; SPIRITUAL CARE; TERMINAL CARE;

EID: 84954197363     PISSN: 09736883     EISSN: 22133453     Source Type: Journal    
DOI: 10.1016/j.jceh.2014.03.049     Document Type: Review

References (76)

1. McCracken M, Olsen M, Chen Jr MS, et al. Cancer incidence, mortality, and associated risk factors among Asian Americans of Chinese, Filipino, Vietnamese, Korean, and Japanese ethnicities. CA Cancer J Clin. 2007;57:190-205.
2. Bosch FX. Global epidemiology of hepatocellular carcinoma. In: Okuda K, Tabor E, eds. Liver Cancer. New York: Churchill Livingstone 1997:13-27.
3. Annual Report 1987. National Cancer Registry Programme. New Delhi, Indian Council of Medical Research, 1990.
4. Jayant K, Rao RS, Nene BM, Dale PS. Rural cancer registry at Barshi-report 1988-92. Barshi: Rural Cancer Registry; 1994.
5. Park YM. Hepatocellular carcinoma in Asia. In: Sarin SK, Okuda K, eds. Hepatitis B and C. Carrier to Cancer. India: Elsevier Sciences; 2002:268-271.
6. Pyrsopoulos N, Reddy RK. Hepatocellular carcinoma in Asia. In: Sarin SK, Okuda K, eds. Hepatitis B and C. Carrier to Cancer. India: Elsevier Sciences; 2002:363-364.
7. Asim M, Sarma MP, Kar P. Aetiological and molecular profile of hepatocellular cancer from India. Int J Cancer. 2013 Jul 15; 133(2):437-445.
8. PaulSB,ChalamalasettySB, Vishnubhatla S, et al.Clinical profile, etiology and therapeutic outcome in 324 hepatocellular carcinoma patients at a tertiary care center in India. Oncology. 2009;77:162-171.
9. Kumar R, Saraswat MK, Sharma BC, Sakhuja P, Sarin SK. Characteristics of hepatocellular carcinoma in India: a retrospective analysis of 191 cases. QJM. 2008 Jun;101:479-485.
10. Kumar M, Kumar R, Hissar SS, et al. Risk factors analysis for hepatocellular carcinoma in patients with and without cirrhosis: a casecontrol study of 213 hepatocellular carcinoma patients from India. J Gastroenterol Hepatol. 2007;22:1104-1111.
11. Zhu AX. Hepatocellular carcinoma: are we making progress? Cancer Invest. 2003;21:418-428.
12. European Association for the Study of the Liver, European Organisation for Research and Treatment of Cancer. EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol. 2012;56:908-943.
13. Llovet JM, Brú C, Bruix J. Prognosis of hepatocellular carcinoma: the BCLC staging classification. Semin Liver Dis. 1999;19:329-338.
14. Cabibbo G, Maida M, Genco C, et al. Natural history of untreatable hepatocellular carcinoma: a retrospective cohort study. World J Hepatol. 2012;27(4):256-261.
15. Cabibbo G, Enea M, Attanasio M, Bruix J, Craxì A, Cammà C. A meta-analysis of survival rates of untreated patients in randomized clinical trials of hepatocellular carcinoma. Hepatology. 2010;51:1274-1283.
16. http://www.who.int/cancer/palliative/definition/en/. Accessed 19.12.12.
17. Lin MH, Wu PY, Tsai ST, Lin CL, Chen TW, Hwang SJ. Hospice palliative care for patients with hepatocellular carcinoma in Taiwan. Palliat Med. 2004;18:93-99.
18. Zabora J, BrintzenhofeSzoc K, Curbow B, Hooker C, Piantadosi S. The prevalence of psychological distress by cancer site. Psychooncology. 2001;10:19-28.
19. Kim HJ, McGuire DB, Tulman L, Barsevick AM. Symptom clusters: concept analysis and clinical implications for cancer nursing. Cancer Nurs. 2005;28:270-282.
20. Ryu E, Kim K, Cho MS, Kwon IG, Kim HS, Fu MR. Symptom clusters and quality of life in Korean patients with hepatocellular carcinoma. Cancer Nurs. 2010;33(1):3-10.
21. Miaskowski C, Dodd M, Lee K. Symptom clusters: the new frontier in symptom management research. J Natl Cancer Inst Monographs. 2004;32:17-21.
22. Mercadante S. Abdominal pain. In: Ripamonti C, Bruera E, eds. Gastrointestinal Symptoms in Advanced cancer Patients. New York: Oxford University Press, Inc; 2002:223-234.
23. Hamilton J, Runyon B, Bonis P, et al.Management of pain in patients with cirrhosis. uptodateonline.com. http://uptodateonline.com/ online/content/topic.do?topicKey=cirrhosi/11256&selectedTitle =1~150&source=search result. Updated May 21, 2009.
24. Clària J, Kent JD, López-Parra M, et al. Effects of celecoxib and naproxen on renal function in nonazotemic patients with cirrhosis and ascites. Hepatology. 2005;41:579-587.
25. Crotty B, Watson KJ, Desmond PV, et al. Hepatic extraction of morphine is impaired in cirrhosis. Eur J Clin Pharmacol. 1989;36:501-506.
26. Hasselström J, Eriksson S, Persson A, et al. The metabolism and bioavailability of morphine in patients with severe liver cirrhosis. Br J Clin Pharmacol. 1990;29:289-297.
27. Mazoit JX, Sandouk P, Zetlaoui P, Scherrmann JM. Pharmacokinetics of unchanged morphine in normal and cirrhotic subjects. Anesth Analg. 1987;66:293-298.
28. Klotz U, McHorse TS, Wilkinson GR, Schenker S. The effect of cirrhosis on the disposition and elimination of meperidine in man. Clin Pharmacol Ther. 1974;16:667-675.
29. Pond SM, Tong T, Benowitz NL, et al. Presystemic metabolism of meperidine to normeperidine in normal and cirrhotic subjects. Clin Pharmacol Ther. 1981;30:183-188.
30. Chandok N, Watt KD. Pain management in the cirrhotic patient: the clinical challenge. Mayo Clin Proc. 2010;85:451-458.
31. Tegeder I, Lötsch J, Geisslinger G. Pharmacokinetics of opioids in liver disease. Clin Pharm. 1999;37:17-40.
32. Haberer JP, Schoeffler P, Couderc E, Duvaldestin P. Fentanyl pharmacokinetics in anaesthetized patients with cirrhosis. Br J Anaesth. 1982;54:1267-1270.
33. Novick DM, Kreek MJ, Arns PA, et al. Effect of severe alcoholic liver disease on the disposition of methadone in maintenance patients. Alcohol Clin Exp Res. 1985;9:349-354.
34. Lewis JH, Stine JG. Review article: prescribing medications in patients with cirrhosis-a practical guide. Aliment Pharmacol Ther. 2013;37:1132-1156.
35. Benson GD. Acetaminophen in chronic liver disease. Clin Pharmacol Ther. 1983;33:95-101.
36. Zimmerman HJ, Maddrey WC. Acetaminophen (paracetamol) hepatotoxicity with regular intake of alcohol: analysis of instances of therapeutic misadventure. Hepatology. 1995;22:767-773.
37. Paulsen É, Aass N, Kaasa S, Dale O. Do corticosteroids provide analgesic effects in cancer patients? A systematic literature review. J Pain Symptom Manage. 2013;46:96-105.
38. Koyyalagunta D, Bruera E, Solanki D, et al. A systematic review of randomized trials on the effectiveness of opioids for Cancer pain. Pain Physician. 2012;15:ES39-ES58.
39. Ingold JA, Reed GB, Kaplan HS, Bagshaw MA. Radiation hepatitis. Am J Roentgenol Radium Ther Nucl Med. 1965;93:200-208.
40. Lawrence TS, Ten Haken RK, Kessler ML, et al. The use of 3-D dose volume analysis to predict radiation hepatitis. Int J Radiat Oncol Biol Phys. 1992;23:781-788.
41. Jiang W, Zeng ZC, Zhang JY, Fan J, Zeng MS, Zhou J. Palliative radiation therapy for pulmonary metastases from hepatocellular carcinoma. Clin Exp Metastasis. 2012;29:197-205.
42. Nakashima T, Okuda K, Kojiro M, et al. Pathology of hepatocellular carcinoma in Japan. Cancer. 1983;51:863-877.
43. Yoon SM, Kim JH, Choi EK, et al. Radioresponse of hepatocellular carcinoma-treatment of lymph node metastasis. Cancer Res Treat. 2004;36:79-84.
44. Zeng ZC, Tang ZY, Fan J, et al. Consideration of role of radiotherapy for lymph node metastases in patients with HCC: retrospective analysis for prognostic factors from 125 patients. Int J Radiat Oncol Biol Phys. 2005;15(63):1067-1076.
45. Seong J, Koom WS, Park HC. Radiotherapy for painful bone metastases from hepatocellular carcinoma. Liver Int. 2005;25:261-265.
46. Kaizu T, Karasawa K, Tanaka Y, et al. Radiotherapy for osseous metastases from hepatocellular carcinoma: a retrospective study of 57 patients. Am J Gastroenterol. 1998;93:2167-2171.
47. He J, Zeng ZC, Tang ZY, et al. Clinical features and prognostic factors in patients with bone metastases from hepatocellular carcinoma receiving external beam radiotherapy. Cancer. 2009 Jun 15;115:2710-2720.
48. Nakamura N, Igaki H, Yamashita H, et al. A retrospective study of radiotherapy for spinal bone metastases from hepatocellular carcinoma (HCC). Jpn J Clin Oncol. 2007;37:38-43.
49. Kodama H, Aikata H, Uka K, et al. Efficacy of percutaneous cementoplasty for bone metastasis from hepatocellular carcinoma. Oncology. 2007;72(5-6):285-292.
50. Choi HJ, Cho BC, Sohn JH, et al. Brain metastases from hepatocellular carcinoma: prognostic factors and outcome: brain metastasis from HCC. J Neurooncol. 2009;91:307-313.
51. Hsu WC, Tsai AC, Chan SC, Wang PM, Chung NN. Mini-nutritional assessment predicts functional status and quality of life of patients with hepatocellular carcinoma in Taiwan. Nutr Cancer. 2012;64:543-549.
52. Pinato DJ, North BV, Sharma R. A novel, externally validated inflammation-based prognostic algorithm in hepatocellular carcinoma: the prognostic nutritional index (PNI). Br J Cancer. 2012;106:1439-1445.
53. Fan ST, Lo CM, Lai EC, Chu KM, Liu CL, Wong J. Perioperative nutritional support in patients undergoing hepatectomy for hepatocellular carcinoma. N Engl J Med. 1994;331:1547-1552.
54. San-in Group of Liver Surgery. Long-term oral administration of branched chain amino acids after curative resection of hepatocellular carcinoma: a prospective randomized trial. Br J Surg. 1997;84:1525-1531.
55. Meng WC, Leung KL, Ho RL, Leung TW, Lau WY. Prospective randomized control study on the effect of branched-chain amino acids in patients with liver resection for hepatocellular carcinoma. Aust N Z J Surg. 1999;69(11):811-815.
56. Poon RT, Yu WC, Fan ST, Wong J. Long-term oral branched chain amino acids in patients undergoing chemoembolization for hepatocellular carcinoma: a randomized trial. Aliment Pharmacol Ther. 2004;19(7):779-788.
57. Kobashi H, Morimoto Y, Ito T, et al. Effects of supplementation with a branched-chain amino acid-enriched preparation on event-free survival and quality of life in cirrhotic patients with hepatocellular carcinoma. A multicenter, randomized controlled trial (Abstract). Gastroenterology. 2006;130:A497.
58. Takeshita S, Ichikawa T, Nakao K, et al. A snack enriched with oral branched chain amino acids prevents a fall in albumin in patients with liver cirrhosis undergoing chemoembolization for hepatocellular carcinoma. Nutr Res. 2009;29:89-93.
59. Koretz RL, Avenell A, Lipman TO. Nutritional support for liver disease. Cochrane Database Syst Rev. 2012 May 16;5:CD008344.
60. Ravasco P, Monteiro-Grillo I, Vidal PM, Camilo ME. Cancer: disease and nutrition are key determinants of patients' quality of life. Support Care Cancer. 2004;12:246-252.
61. Ockenga J, Valentini L. Review article: anorexia and cachexia in gastrointestinal cancer.Aliment Pharmacol Ther.2005;22:583-594.
62. Del Fabbro E, Dalal S, Bruera E. Symptom control in palliative care-part ii: cachexia/anorexia and fatigue. J Palliat Med. 2006;9:409-421.
63. Lopez A, Roque Figuls M, Cuchi G. Systematic review of megestrol acetate in the treatment of anorexiacachexia syndrome. J Pain Symptom Manage. 2004;27:360-369.
64. Muscaritoli M, Bossola M, Aversa Z, Bellantone R, Rossi Fanelli F. Prevention and treatment of cancer cachexia: new insights into an old problem. Eur J Cancer. 2006;42:31-41.
65. Ravasco P, Monteiro-Grillo I, Vidal PM, Camilo ME. Dietary counseling improves patient outcomes: a prospective, randomized, controlled trial in colorectal cancer patients undergoing radiotherapy. J Clin Oncol. 2005;23:1431-1438.
66. Mock V. Evidence-based treatment for cancer-related fatigue. J Natl Cancer Inst Monographs. 2004;32:112-118.
67. Bruera E, Valero V, Driver L, et al. Patient-controlled methylphenidate for cancer fatigue: a double-blind, randomized, placebocontrolled trial. J Clin Oncol. 2006;24:2073-2078.
68. Puetz TW, Herring MP. Differential effects of exercise on cancerrelated fatigue during and following treatment: a meta-analysis. Am J Prev Med. 2012 Aug;43(2):e1-24.
69. Lichter I. Results of antiemetic management in terminal illness. J Palliat Care. 1993;9:19.
70. Stephenson J, Davies A. An assessment of aetiology-based guidelines for the management of nausea and vomiting in patients with advanced cancer. Support Care Cancer. 2006;14:348-353.
71. Bergasa NV. Pruritus in chronic liver disease: mechanisms and treatment. Curr Gastroenterol Rep. 2004 Feb;6(1):10-16.
72. Tarumi Y, Wilson MP, Szafran O, Spooner GR. Randomized, doubleblind, placebo-controlled trial of oral docusate in the management of constipation in hospice patients. J Pain Symptom Manage. 2013;45:2-13.
73. Hawley PH, Byeon JJ. A comparison of sennosides-based bowel protocols with and without docusate in hospitalized patients with cancer. J Palliat Med. 2008;11:575-581.
74. Bruhn JG. Therapeutic value of hope. Southampt Med J. 1984;77:215-219.
75. Block SD. Perspectives on care at the close of life. Psychological considerations, growth, and transcendence at the end of life: the art of the possible. JAMA. 2001;285:2898-2905.
76. Williams S, Dale J. The effectiveness of treatment for depression/ depressive symptoms in adults with cancer: a systematic review. Br J Cancer. 2006;94:372-390.